Contact Us
Novel Immunotherapy

Technology

Developing therapeutic agents for the treatment of cancer based on the invention of Professor Shisong Jiang – Recombinant Overlapping Peptides (ROP)
ITN Business - Advancing Immunology

Technology

The immune system employs specialised agents to attack particular targets on invading organisms and tumours. These are both antibodies or a type of T Cells (often called cytotoxic T Lymphocytes or CTL). These CTLs are produced when a T Cell encounters a protein or other molecule it considers to be foreign and not normally found in the body. The T Cell that recognises these foreign agents is then multiplied to mount an attack against the invading organism or tumour.

With over 90% of health decisions based on diagnostic results, we are committed to being a trusted healthcare partner. Contact Us

Recombinant Overlapping Peptides (ROP)

Tumours can often avoid being targeted by these T Cells by looking like a cell found normally in the body often referred to as “self”. If a group of T Cells can be encouraged to recognise these tumours as foreign and not ‘self’ then they will attack the tumour and provide an effective treatment against it.
Injecting a preparation that stimulates both B cell antibodies and T Cells effectively vaccinates the patient against the tumour providing both immediate treatment and potentially longer term protection against the cancer returning. The Oxford Vacmedix technology – the Recombinant Overlapping Peptides – is a powerful new immunotherapy approach that delivers just this result.
Injecting a preparation that stimulates both B cell antibodies and T Cells effectively vaccinates the patient against the tumour providing both immediate treatment and potentially longer term protection against the cancer returning. The Oxford Vacmedix technology – the Recombinant Overlapping Peptides – is a powerful new immunotherapy approach that delivers just this result.
The way the ROP is designed creates a vaccine that mimics a mutated form of the target protein or antigen (this is known as a neoantigen), while still preserving all the original T cell and B cell epitopes. This innovative approach generates much stronger immune responses than a vaccine based on the natural protein, which is perceived by the immune system as a self-protein and therefore less immunogenic.

Overlapping peptides have been found to be highly effective in providing treatment for cervical cancer in early work (Ref Kenter et al., New England Journal of Medicine, 2009, 361: 1838 – 1847). These materials had to be produced synthetically making them both expensive and hard to produce consistently.

The patented Recombinant Overlapping approach produces a much more effective vaccine which is both highly immunogenic as well as being simpler and more economical to produce.

Patented Overlapping Approach

The patented Recombinant Overlapping approach produces a much more effective vaccine which is both highly immunogenic as well as being simpler and more economical to produce.

Dual Mode of Action

The combination of Tcells and antibodies produces an exceptionally strong immunotherapy attack on the cancer tumour.

Redefines personalised medicine

The ROP technology converts the target protein (a Tumour Associated Antigen) into a Tumour Specific Antigen, applicable to all HLA types

Dual Mode of Action

By mimicking a mutated form of the antigen the ROP aims to enhance the immune response to this antigen and provide better protection against cancer cells that express it.

Subcutaneous administration of the ROP leads to endosomal uptake into the antigen presenting cells, where the ROP is cleaved by cathepsin S, into individual peptides.
These peptides are cross presented on MHC class I molecules efficiently, and produce a very strong CTL (CD8) effect. In parallel the CD4 helper T cells also help stimulate a very strong and long lasting antibody effect.

The combination of Tcells and antibodies – the dual mode of action - produces an exceptionally strong immunotherapy attack on the cancer tumour.
These peptides are cross presented on MHC class I molecules efficiently, and produce a very strong CTL (CD8) effect. In parallel the CD4 helper T cells also help stimulate a very strong and long lasting antibody effect.

The combination of Tcells and antibodies – the dual mode of action - produces an exceptionally strong immunotherapy attack on the cancer tumour.
ROP Dual Mode of Action
Novel Immunotherapy and Beyond

ROP Applications – Licensing Opportunities

With over 90% of health decisions based on diagnostic results, we are committed to being a trusted healthcare partner. Contact Us
Novel Immunotherapy and Beyond

ROP Applications - Licensing Opportunities

Oxford Vacmedix is developing new immunotherapy vaccines to treat cancer.
But the ROP technology has much wider applications, from cancer to infectious disease, from therapeutics to diagnostics, from human health to veterinary applications.
1

Oncology Therapies

ROPs developed as therapeutic cancer vaccines
More Info
2

Diagnostics

CBIG : world-class, global Dx using ROPs
More Info
3

Veterinary

Veterinary vaccines & diagnostics
More Info
4

Infectious Diseases

Theraputics for infectious diseases
Request more info

Swipe left to see more…

cms-header-icon-molecule

Licensing opportunities for infectious disease and veterinary

Oxford Vacmedix is interested in collaborating with leading pharma companies that can provide checkpoint inhibitors suitable for combination with the novel ROP vaccines.

University of Oxford logo

More info...

The immune system employs specialised agents to attack particular targets on invading organisms and tumours. These are both antibodies or a type of T Cells (often called cytotoxic T Lymphocytes or CTL). These CTLs are produced when a T Cell encounters a protein or other molecule it considers to be foreign and not normally found in the body. The T Cell that recognises these foreign agents is then multiplied to mount an attack against the invading organism or tumour.

With over 90% of health decisions based on diagnostic results, we are committed to being a trusted healthcare partner. Contact Us
en_GBEnglish
en_GBEnglish